There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iovance Biotherapeutics Inc (IOVA) and AzurRx BioPharma Inc (AZRX) with bullish sentiments.
Iovance Biotherapeutics Inc (IOVA)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Iovance Biotherapeutics Inc today and set a price target of $32.00. The company’s shares closed last Monday at $18.79.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -10.2% and a 32.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Applied Genetic Technologies, and Checkpoint Therapeutics Inc.
Currently, the analyst consensus on Iovance Biotherapeutics Inc is a Strong Buy with an average price target of $30.83.
See today’s analyst top recommended stocks >>
AzurRx BioPharma Inc (AZRX)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on AzurRx BioPharma Inc today and set a price target of $5.00. The company’s shares closed last Monday at $0.70, close to its 52-week low of $0.64.
According to TipRanks.com, Chen has 0 stars on 0-5 star ranking scale with an average return of -19.2% and a 28.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Stealth Biotherapeutics Corp, and Aerpio Pharmaceuticals Inc.
AzurRx BioPharma Inc has an analyst consensus of Moderate Buy, with a price target consensus of $4.00, implying a 471.4% upside from current levels. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $3.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.